* Gliatech Inc., of Cleveland, reached agreement with the FDA on labeling for ADCON-L, an anti-scarring gel. ADCON-L Anti-Adhesion Barrier Gel is a carbohydrate polymer gel designed to physically block formation of excess scar tissue. The gel is completely reabsorbed by the body in four weeks. Gliatech expects to receive final FDA approval in mid-1998.

* Stryker Corp., of Kalamazoo, Mich., and Creative BioMolecules Inc., of Hopkinton, Mass., said analysis of data in a clinical trial of Stryker's OP-1 device showed comparable clinical success to the autograft group, without the need for a second invasive procedure to harvest autograft bone from the hip. OP-1 is a genetically engineered bone morphogenetic protein for use as a bone graft material. Under co-development by Stryker and Creative BioMolecules, the device combines the protein and a resorbable collagen scaffold designed to be surgically implanted in bone fractures and defects. The proteins activate a highly specialized bone cell reaction that induces bone regeneration. (See BioWorld Today, June 9, 1997, p. 1.)

No Comments